Related references
Note: Only part of the references are listed.Implementation of Cholesterol-Lowering Therapy to Reduce Cardiovascular Risk in Persons Living with HIV
Stephani C. Wang et al.
CARDIOVASCULAR DRUGS AND THERAPY (2022)
Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association
Gissette Reyes-Soffer et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2022)
Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)-Free Low-Density Lipoprotein Cholesterol
Weili Zheng et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2022)
Lipoprotein(a), a Lethal Player in Calcific Aortic Valve Disease
Jiahui Hu et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)
Cascade screening for familial hypercholesterolemia should be organized at a national level
Trond P. Leren et al.
CURRENT OPINION IN LIPIDOLOGY (2022)
Accuracy and Clinical Impact of Estimating Low-Density Lipoprotein-Cholesterol at High and Low Levels by Different Equations
Maureen Sampson et al.
BIOMEDICINES (2022)
Lipoprotein(a)-When to Screen and How to Treat
Neeja Patel et al.
CURRENT CARDIOVASCULAR RISK REPORTS (2022)
Lipoprotein Assessment in the twenty-first Century
Diego Lucero et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2022)
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Donald M. Lloyd -Jones et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)
Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes
Paul Lacaze et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)
Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk
Tamara Glavinovic et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2022)
Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome
Gianni Biolo et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)
Examining the Nocebo Effect of Statins Through Statin Adverse Events Reported in the Food and Drug Administration Adverse Event Reporting System
Jungyeon Moon et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2021)
ANGPTL3 as therapeutic target
Sander Kersten
CURRENT OPINION IN LIPIDOLOGY (2021)
Familial Hypercholesterolemia JACC Focus Seminar 4/4
Julia Brandts et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Role of Bempedoic Acid in Clinical Practice
Christie M. Ballantyne et al.
CARDIOVASCULAR DRUGS AND THERAPY (2021)
Hydrophilic or Lipophilic Statins?
Elisenda Climent et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
Adherence and persistence in the use of statins and ezetimibe over 8 years in a real-life study
Fiorenzo Santoleri et al.
CURRENT MEDICAL RESEARCH AND OPINION (2021)
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)
Frank L. J. Visseren et al.
EUROPEAN HEART JOURNAL (2021)
Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia
Nagham N. Hindi et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group
Peter W. F. Wilson et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2021)
Satin therapy increases lipoprotein(a) levels
Sotirios Tsimikas et al.
EUROPEAN HEART JOURNAL (2020)
Method development for quantitative determination of seven statins including four active metabolites by means of high-resolution tandem mass spectrometry applicable for adherence testing and therapeutic drug monitoring
Lea Wagmann et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2020)
Inclisiran-New hope in the management of lipid disorders?
Krzysztof Dyrbus et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2020)
Drug-Induced Liver Injury from Statins
Lindsay Meurer et al.
CLINICS IN LIVER DISEASE (2020)
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
Jan Boren et al.
EUROPEAN HEART JOURNAL (2020)
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia
Maureen Sampson et al.
JAMA CARDIOLOGY (2020)
Measuring LDL-cholesterol: what is the best way to do it?
Anna Wolska et al.
CURRENT OPINION IN CARDIOLOGY (2020)
Reasons for Nonadherence to Statins - A Systematic Review of Reviews
Marianne Vie Ingersgaard et al.
PATIENT PREFERENCE AND ADHERENCE (2020)
Worldwide Prevalence of Familial Hypercholesterolemia Meta-Analyses of 11 Million Subjects
Sabina O. Beheshti et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Measuring the contribution of Lp(a) cholesterol towards LDL-C interpretation
Erica M. Fatica et al.
CLINICAL BIOCHEMISTRY (2020)
Diminished response to statins predicts the occurrence of heart failure after acute myocardial infarction
Kosuke Tsuda et al.
CARDIOVASCULAR DIAGNOSIS AND THERAPY (2020)
Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization
Kristina A. Malsagova et al.
PHARMACEUTICS (2020)
Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol A Randomized Clinical Trial
Jason L. Vassy et al.
JAMA NETWORK OPEN (2020)
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease
Ralph Kwame Akyea et al.
HEART (2019)
LDL Cholesterol: What Is the Best Way to Measure It?
Anna Wolska et al.
CLINICAL CHEMISTRY (2019)
Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain
Luis Masana et al.
ATHEROSCLEROSIS (2019)
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
Francois Mach et al.
ATHEROSCLEROSIS (2019)
Pharmacogenetics of statins treatment: Efficacy and safety
Zi-Wan Guan et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2019)
Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options
Kausik K. Ray et al.
LANCET (2019)
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
Ulf Landmesser et al.
EUROPEAN HEART JOURNAL (2018)
Dyslipidaemia in nephrotic syndrome: mechanisms and treatment
Shipra Agrawal et al.
NATURE REVIEWS NEPHROLOGY (2018)
Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
Christie M. Ballantyne et al.
ATHEROSCLEROSIS (2018)
Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins Prespecified Secondary End Points in ORION 1
Kausik K. Ray et al.
CIRCULATION (2018)
The optimal time of day for statin administration: a review of current evidence
Kamal Awad et al.
CURRENT OPINION IN LIPIDOLOGY (2018)
Influence of hypercholesterolemia on serum antibodies against oxidized LDL in children and adolescents
Anastasia Garoufi et al.
PEDIATRICS INTERNATIONAL (2018)
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study
Manuela Casula et al.
ATHEROSCLEROSIS (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The effects of bile acid sequestrants on lipid profile and blood glucose concentrations: A systematic review and meta-analysis of randomized controlled trials
Mohsen Mazidi et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
A Test in Context: Lipoprotein(a) Diagnosis, Prognosis, Controversies, and Emerging Therapies
Sotirios Tsimikas
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Mark J. Graham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
F. E. Dewey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder
Charlotte Koopal et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2017)
Management of patients with statin intolerance
Sabine Fischer et al.
ATHEROSCLEROSIS SUPPLEMENTS (2017)
Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) Insights From the Department of Veterans Affairs
Salim S. Virani et al.
CIRCULATION (2017)
Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies
S. Trompet et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents
Paul M. Ridker et al.
EUROPEAN HEART JOURNAL (2016)
The panorama of familial hypercholesterolemia in Latin America: a systematic review
Roopa Mehta et al.
JOURNAL OF LIPID RESEARCH (2016)
Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel
Raul D. Santos et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Atheroma Progression in Hyporesponders to Statin Therapy
Yu Kataoka et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
Erik S. Stroes et al.
EUROPEAN HEART JOURNAL (2015)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
Marina Cuchel et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2015)
Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation
Gerald F. Watts et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2015)
Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia
Paulo Caleb Junior Lima Santos et al.
ATHEROSCLEROSIS (2014)
Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
Amit V. Khera et al.
CIRCULATION (2014)
The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins
Lech Chrostek et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2014)
Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin
Ling He et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Resistance and intolerance to statins
Z. Reiner
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2014)
Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins
Iris Postmus et al.
NATURE COMMUNICATIONS (2014)
Improving medication adherence in hypercholesterolemia: challenges and solutions
Justin Gatwood et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2014)
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
Marina Cuchel et al.
EUROPEAN HEART JOURNAL (2014)
Prediction of LDL cholesterol response to statin using transcriptomic and genetic variation
Kyungpil Kim et al.
GENOME BIOLOGY (2014)
How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy?
Patricia Maningat et al.
CURRENT ATHEROSCLEROSIS REPORTS (2013)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2013)
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
Marina Cuchel et al.
LANCET (2013)
Nonadherence to Statin Therapy: Discontinuation After a Single Fill
Mark Lemstra et al.
CANADIAN JOURNAL OF CARDIOLOGY (2012)
Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI
Bas J. M. Peters et al.
ATHEROSCLEROSIS (2011)
Hyperlipidemic myeloma: review of 53 cases
Benjamin Misselwitz et al.
ANNALS OF HEMATOLOGY (2010)
Utilization patterns of extended-release niacin in Canada: Analysis of an administrative claims database
Marc Dorais et al.
CANADIAN JOURNAL OF CARDIOLOGY (2010)
Seven Direct Methods for Measuring HDL and LDL Cholesterol Compared with Ultracentrifugation Reference Measurement Procedures
W. Greg Miller et al.
CLINICAL CHEMISTRY (2010)
Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study
Kåre Berg et al.
CLINICAL GENETICS (2010)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2010)
Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction
Bas J. M. Peters et al.
PHARMACOGENOMICS (2010)
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy
S. P. R. Romaine et al.
PHARMACOGENOMICS JOURNAL (2010)
Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy
Daniel I. Chasman et al.
ATHEROSCLEROSIS (2009)
Clinical implications of pharmacogenomics of statin treatment
L. M. Mangravite et al.
PHARMACOGENOMICS JOURNAL (2006)
Identification of autoantibodies in human plasma recognizing an apoB-100 LDL receptor binding site peptide
Gunilla Nordin Fredrikson et al.
JOURNAL OF LIPID RESEARCH (2006)
Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction
GH Gislason et al.
EUROPEAN HEART JOURNAL (2006)
Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients -: The PRIMO study
E Bruckert et al.
CARDIOVASCULAR DRUGS AND THERAPY (2005)
The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment
M Fiegenbaum et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Drug therapy - Adherence to medication
L Osterberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cascade testing in familial hypercholesterolaemia: how should family members be contacted?
AJ Newson et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2005)
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
M Schachter
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2005)
Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8)
K Letschert et al.
PHARMACOGENETICS (2004)
Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment
TA Miettinen et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2003)
Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin
T Kosoglou et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Why some patients respond poorly to statins and how this might be remedied
GR Thompson et al.
EUROPEAN HEART JOURNAL (2002)
Share Paper
